NASDAQ$NPCE
Neuropace Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
NeuroPace reported Q4 2025 revenue of $26.6M (+24% YoY) with positive adjusted EBITDA of $0.9M.
Fourth-quarter total revenue was $26.6 million (+24%), with RNS System revenue of $22.4 million (+26%). Gross margin was 77.4% (RNS 80.5%). Adjusted EBITDA was $0.9 million for the second consecutive quarter. Cash was $61.1 million. Full-year revenue was $100.0 million (+25%). Management reiterated 2026 core RNS revenue growth of 20–22% excluding potential IGE contribution after mid-2026 PMA-S decision.
- Q4 revenue $26.6M (+24%); RNS revenue $22.4M (+26%).
- Adjusted EBITDA $0.9M; cash $61.1M.
- FY25 revenue $100.0M (+25%).
- NAUTILUS PMA-S submitted for IGE indication.
- Medicare reimbursement increases for 2026 procedures.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$26.6M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
2026 core RNS revenue growth 20–22% excluding IGE; potential IGE contribution after mid-2026 PMA-S approval.
Tailwinds
- Second consecutive quarter of positive adjusted EBITDA.
- Strong RNS implant growth and prescriber highs.
- Favorable CMS reimbursement changes for 2026.
Headwinds
- Still near breakeven on adjusted EBITDA for full year.
- IGE upside dependent on regulatory timing.
- Single-product commercial concentration.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.0%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | +0.8% | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro